About T2 Biosystems
T2 Biosystems is a publicly listed company based in Lexington (United States) founded in 2006. Miniaturized MRI platforms for clinical diagnostics are developed. T2 Biosystems has raised $454.3 million across 11 funding rounds from investors including Goldman Sachs, Canon and NIH. Its chief executive, as recorded, is John Sperzel. T2 Biosystems offers products and services including Diagnostic Products. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified. Its legal entity is T2 Biosystems, Inc. Its competitors include Inflammatix, Visby Medical and GenMark Diagnostics; 3 of its 3 listed competitors have raised funding.
Company details
T2 Biosystems was founded in 2006 in Lexington, United States, with operations centered in the biotechnology sector. Miniaturized magnetic resonance imaging platforms are developed for clinical diagnostics. Pathogens are detected using the proprietary T2MR technology, which measures alterations in water molecule reactions within magnetic fields. Diagnostic panels targeting bacterial septic infections, hemostasis, and Lyme disease are under development.
- Headquarters Lexington, United States
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website t2biosystems.com
- Social LinkedIn X
- Legal Name T2 Biosystems, Inc.
- Annual Revenue$7.19 M (USD)-67.75as on Dec 31, 2023
- Net Profit-$50.08 M (USD)19.23as on Dec 31, 2023
- EBITDA-$46.29 M (USD)10.58as on Dec 31, 2023
- Total Equity Funding$454.3M (USD)
in 11 rounds
- Latest Funding Round$2M (USD), Grant
Mar 2018
- InvestorsGoldman Sachs
& 15 more
Products & Services of T2 Biosystems
T2 Biosystems offers a comprehensive portfolio of products and services, including Diagnostic Products.
Tools for in vitro testing in healthcare settings
Funding Insights of T2 Biosystems
T2 Biosystems has successfully raised a total of $454.3M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $2 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $454.3M
- Total Rounds 11
- Last Round Grant — $2M
- First Round $5.5M
(Jan 2006)
- Investors Count 16
Latest 10 of 11 funding rounds of T2 Biosystems with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2018 | $2M | Grant | – | – | |
| Jan 2017 | $50M | Debt – Conventional | – | – | |
| Sep 2016 | $40M | Post-IPO | – | – | |
| Mar 2013 | $400M | Series E | – | Goldman Sachs | |
| Aug 2011 | $23M | Series D | – | Aisling Capital, Arcus Ventures | |
| Nov 2010 | $73,000 | Grant | – | – | |
| May 2010 | $15M | Series C | – | Physic Ventures | |
| Jan 2010 | $1.4M | Grant | – | – | |
| Sep 2009 | $2.77M | Grant | – | – | |
| Oct 2008 | $10.8M | Series B | – | Flybridge Capital Partners, Polaris Partners | – |
16 investors in total: 16 institutional.
Investors in T2 Biosystems
T2 Biosystems has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, Canon and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CRG is recognized as a premier healthcare investment partner. | crglp.com | Houston, United States | ||
Early-stage tech startups are funded by Flybridge Capital Partners. | flybridge.com | New York, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
| physicventures.com | ||||
| camros-capital.com | ||||
Investment banking services are delivered across multiple financial sectors. | 1869 | goldmansachs.com | New York, United States | |
Arcus Ventures is focused on investing in oncology companies. | arcusventures.com | New York, United States | ||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. | 2016 | carb-x.org | Boston, United States |
Investor details for T2 Biosystems
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of T2 Biosystems
20 people are tracked at T2 Biosystems (8 in leadership, 6 in board & advisors, 6 in team).
| Name | Role | Group |
|---|---|---|
John Sperzel | CEO | Leadership |
John Sprague | Chief Financial Officer | Leadership |
Jason Kniebel | Vice President, US Sales | Leadership |
Casey Prior | Director, Finance | Leadership |
Merel Broek-Kühbauch | International Business Director | Leadership |
Brett Giffin | Chief Commercial Officer | Leadership |
Lee Josephson | Co-Founder and Consultant | Leadership |
Sandy J. Estrada | Vice President, Medical Affairs | Leadership |
Ninfa M. Saunders | Director | Board & advisors |
Thierry Bernard | Director | Board & advisors |
John W. Cumming | Director | Board & advisors |
Seymour Liebman | Director | Board & advisors |
David Elsbree | Director | Board & advisors |
Laura Adams | Director | Board & advisors |
Sana V. | Medical Affairs Manager | Team |
Abiola A. | Customer Success Manager | Team |
Tammy Morrison-Spurr | Corporate Controller | Team |
Sarah Parker | Regional Account Manager | Team |
Roger Smith | SVP, Science, Research & Development | Team |
Aisha Hedden | Regional Account Manager | Team |
Complete people profiles for T2 Biosystems
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of T2 Biosystems
T2 Biosystems is a publicly listed company on the OTC with ticker symbol TTOO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Aug 2014
- Listed onNASDAQ: TTOO
- Listed entityT2 Biosystems, Inc.
- Exchange sectorHealth technology
- ISINUS89853L3024
- Share price$0.00 (+14.29% on the day) · 2026-10-12
- Market capitalisation$22,436.00
- Volume (last session)7,783
Financials of T2 Biosystems
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2023 | $7.2M | -$50.1M | -$46.3M |
| 2022 | $22.3M | -$62.0M | -$51.8M |
| 2021 | $28.1M | -$49.2M | -$40.4M |
| 2020 | $18.1M | -$46.8M | -$37.0M |
Detailed financial statements for T2 Biosystems
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of T2 Biosystems
4 dated milestones of T2 Biosystems across 12 years, from founding to its latest funding, stage changes and deals.
- Founded T2 Biosystems is founded.
- Funding First funding round of $5.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $2.0M.
Competitors of T2 Biosystems
T2 Biosystems has 3 listed competitors in our database, 3 of them funded. They include Inflammatix, Visby Medical and GenMark Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. |
Detailed competitors of T2 Biosystems
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of T2 Biosystems
The website of T2 Biosystems (t2biosystems.com) receives about 2.4K visits a month and ranks #5,928,921 among all websites worldwide, #6,318 in Biotechnology and Pharmaceuticals.
- Monthly visits2.4K
▼ 12.9% vs previous month
- Unique visitors1.2K
per month
- Global rank#5,928,921
among all websites
- Category rank#6,318
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.7
- Average visit20 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with T2 Biosystems. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bdsi.com | 100% | View details | |||
bioworld.com | bioworld.com | 99% | #311,180 | – | |
mddionline.com | mddionline.com | 71% | #495,326 | – | |
medicaldevices-business-review.com | medicaldevices-business-review.com | 61% | – | ||
| massdevice.com | 61% | #435,992 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for T2 Biosystems
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as T2 Biosystems (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about T2 Biosystems
Complete news archive for T2 Biosystems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about T2 Biosystems
T2 Biosystems was founded in 2006.
T2 Biosystems is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
John Sperzel is the CEO of T2 Biosystems, as recorded in our data.
T2 Biosystems is a funded company, having raised a total of $454.3M across 11 funding rounds to date. The company's 1st funding round was a Series B of $10.8M, raised on Jan 2006.
Annual revenue of T2 Biosystems is $7.19M as on Dec 31, 2023.
T2 Biosystems was founded in 2006 in Lexington, United States, with operations centered in the biotechnology sector. Miniaturized magnetic resonance imaging platforms are developed for clinical diagnostics. Pathogens are detected using the proprietary T2MR technology, which measures alterations in water molecule reactions within magnetic fields. Diagnostic panels targeting bacterial septic infections, hemostasis, and Lyme disease are under development.
T2 Biosystems's top competitors include Visby Medical, Inflammatix and GenMark Diagnostics.
T2 Biosystems offers Diagnostic Products.
Yes, T2 Biosystems is publicly traded on OTC under the ticker symbol TTOO.
T2 Biosystems has 16 investors. Key investors include Goldman Sachs, Canon, NIH, Flagship Pioneering, and DOE.
T2 Biosystems operates through T2 Biosystems, Inc..